NCT00370227View on ClinicalTrials.gov

Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

390

Participants

Timeline

Start Date

October 31, 2006

Study Completion Date

March 31, 2007

Conditions
Infections, Streptococcal
Interventions
BIOLOGICAL

10 valent pneumococcal conjugate (vaccine)

Trial Locations (8)

20520

GSK Investigational Site, Turku

28120

GSK Investigational Site, Pori

33100

GSK Investigational Site, Tampere

90100

GSK Investigational Site, Oulu

00930

GSK Investigational Site, Helsinki

04400

GSK Investigational Site, Järvenpää

01300

GSK Investigational Site, Vantaa

01600

GSK Investigational Site, Vantaa

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY